grinboss

Solventum

SOLV

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $86.48 (close on November 18) and with the other assumptions at their starting point, Solventum's sales would need to grow 1.1% a year for ten years; over its last decade, the median was 0.8%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
12/20228,130—21.3%
12/20238,1970.8%21.1%
12/20248,2540.7%13.9%
12/20258,3250.9%28.1%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Solventum files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 0.8% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 21.1% of sales.
  • Working capital needed to grow: −$0.2 per $100 of new sales.
  • Capital spending: 4.0% of sales.
  • Stock pay to employees: 0.7% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Over ten years, its worst fall from a high was 40%; the median is 56%.
  • Its share price moves less than the market: a five-year beta of 0.51; the median is 0.94.
  • Its stock pay to employees comes to 0.7% of sales; the median is 1.5%.
  • It makes $21 of operating profit for every $100 it sells, before stock pay; the median is $18.

Against

  • It is one of the smallest in grinboss: it sells $8.3 billion a year; the median is $15.1 billion.
  • Its capital spending takes 4.0% of its sales every year, more than the median (3.3%).
  • Its net debt equals 1.7 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).

Next results: February 25, 2027.

Other companies in its sector (Health Care)

Steris (STE) · Stryker Corporation (SYK) · Bio-Techne (TECH) · Thermo Fisher Scientific (TMO) · Universal Health Services (UHS) · Vertex Pharmaceuticals (VRTX) · Viatris (VTRS) · Waters Corporation (WAT) · All companies

Loading the model…